Physician profile
Brian W Loskill
NPI 1598764037
$2,188.51
in general payments reported to CMS, 2019-2025
15 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $440 · 2023: $609 · 2024: $307 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $657.27 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $502.19 | 2021-2025 | Xtampza, Belbuca |
| Virtus Pharmaceuticals LLC | $267.32 | 2021-2025 | Levorphanol Tartrate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.40 | 2022-2025 | Relistor |
| Merck Sharp & Dohme LLC | $130.32 | 2022-2023 | Belsomra |
| Scilex Pharmaceuticals INC. | $110.03 | 2021-2023 | Ztlido |
| Biodelivery Sciences International, INC. | $60.50 | 2021 | |
| Eisai INC. | $57.49 | 2021 | |
| Biotronik Nro, INC. | $54.77 | 2025 | Prospera |
| Takeda Pharmaceuticals U.S.A., INC. | $42.77 | 2021 | |
| Grt US Holding, INC. | $29.38 | 2022 | |
| Almatica Pharma LLC | $24.69 | 2021 | |
| Redhill Biopharma INC. | $19.34 | 2021 | |
| Abbott Laboratories | $17.41 | 2024 | Eterna |
| Valinor Pharma, LLC | $16.63 | 2023 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Loskill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.